600056 中国医药
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入17,797,322-17.70%38,824,43137,592,65036,234,41539,311,753
减:营业总成本17,153,291-17.22%37,501,89536,137,94034,480,96436,386,460
    其中:营业成本15,856,033-17.51%34,440,81432,845,78631,018,23932,512,228
               财务费用88,704271.94%112,038138,317221,691257,359
               资产减值损失1,217-173.80%(13,539)(280,660)(575,297)(682,774)
公允价值变动收益(1,109)-3,487.34%9851,922(2,135)656
投资收益1,311-95.83%(15,792)51,00143,65737,514
    其中:对联营企业和合营企业的投资收益23,149-59.91%77,04393,219113,90088,306
营业利润606,653-30.52%1,672,3341,199,698937,1351,939,187
利润总额604,024-30.91%1,640,5561,196,127940,1061,925,266
减:所得税费用154,267-21.91%398,435307,699225,830539,186
净利润449,757-33.54%1,242,120888,428714,2761,386,081
减:非控股权益124,638-6.43%194,081152,82767,21975,435
股东净利润325,119-40.19%1,048,039735,601647,0571,310,646

市场价值指针
每股收益 (元) *0.217-40.20%0.7010.4920.4331.227
每股派息 (元) *0.022--0.2100.1480.1820.368
每股净资产 (元) *7.7343.86%7.7287.230--9.364
审计意见 #--标准无保留意见标准无保留意见标准无保留意见--
回页顶
备注: *未调整数据
#只提供简体内容